Join the AbobotulinumtoxinA group to help and get support from people like you.
AbobotulinumtoxinA News
Ipsen Announces Updated Indication for Dysport (abobotulinumtoxinA) for the Treatment of Spasticity in Children
CAMBRIDGE, Mass.--(BUSINESS WIRE) July 09, 2020 --Ipsen Biopharmaceuticals, an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), announced today that the United States Food and Drug Administration...
Ipsen Announces FDA approval of Dysport (abobotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Adults
June 16, 2017 – Ipsen (Euronext: IPN; ADR: IPSEY) (Ipsen) today announced that the U.S. Food and Drug Administration (FDA) has expanded the approved use of Dysport (abobotulinumtoxinA) for injection...
Ipsen Biopharmaceuticals, Inc. Announces FDA Approval of Dysport (abobotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Pediatric Patients Aged Two and Older
BASKING RIDGE, N.J., Aug. 1, 2016 /PRNewswire/ – Ipsen Biopharmaceuticals, Inc., a subsidiary of Ipsen SA (Euronext: IPN; ADR: IPSEY) (Ipsen), today announced that the U.S. Food and Drug...
Ipsen Announces FDA Approval of Dysport (abobotulinumtoxinA) for Upper Limb Spasticity
Paris (France), 16 July 2015 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental Biologics License Application (sBLA) f...
Further information
Related condition support groups
Facial Wrinkles, Cervical Dystonia